Risk of Bleeding Related to Selective and Non-selective Serotonergic Antidepressants: A Case/Non-case Approach Using Data from Two Pharmacovigilance Databases

Abstract

Introduction: There is increasing evidence for an association between treatment with selective serotonin reuptake inhibitors (SSRI) and an increased risk of bleeding events. The most important underlying mechanism appears to be inhibition of serotonin uptake in platelets, an effect that is also present in antidepressants with non-selective serotonin-reuptake inhibition (NSRI). Accordingly, also NSRI may be associated with an increased risk of bleeding. However, there is little data in this regard.

Methods: Based on data (spontaneous reports of adverse drug reactions) from 2 pharmacovigilance databases (WHO-database/Vigibase^TM; BfArM/AkdÄ-database in Germany) we used a case/non-case approach and calculated reporting odds ratios (ROR) as measures for disproportionality regarding the association of treatment with an agent of the group SSRI/NSRI and haemorrhages.

Results: Whereas both positive control agents (ASS and diclofenac) were statistically associated with haemorrhages in both databases (ASS: BfArM/AkdÄ, ROR 13.62 [95% CI 12.76−14.53]/WHO, ROR 12.96 [95% CI 12.75−13.16]; diclofenac: BfArM/AkdÄ, ROR 3.01 [95% CI 2.71−3.21]/WHO, ROR 2.11 [95% CI 2.05−2.16]), none of the agents of the group SSRI (ROR<1) was associated with haemorrhages. In group NSRI, only St. John’s wort/hypericum was associated with haemorrhages (WHO-database, ROR 1.31 [95% CI 1.06−1.63]).

Discussion: Signal detectioning in 2 pharmacovigilance databases suggest that serotonin reuptake inhibition is not associated with an increased risk of bleeding. However, underreporting may have accounted for the evaluated absent associations, particularly concerning SSRI. Regarding the detected increased risk of bleeding associated with hypericum, pharmacokinetic drug-drug interactions may be relevant independent of serotonin reuptake inhibition.

Key words

haemorrhages - pharmacokinetics - signal detection - WHO

• References

• 1 Mulrow C, Williams JJ, Chiquette E et al. Efficacy of newer medications for treating depression in primary care patients. Am J Med 2000; 108: 54-64
• 2 Sonnenberg C, Deeg D, Comijs H et al. Trends in antidepressant use in older populations: results from the LASA-study over a period of 10 years. J Affect Disord 2008; 111: 299-305
• 3 Lockhart P, Guthrie B. Trend in primary care antidepressant prescribing 1995–2007: a longitudinal population based analysis. Br J Gen Pract 2011; 61: e565-e572
• 4 Hemels M, Koren G, Einarson T. Increased use of antidepressants in Canada: 1981–2000. Ann Pharmacother 2002; 36: 1375-1379
• 5 Percudani M, Barbui C, Fortino I et al. Antidepressant drug use in Lombardy, Italy: a population-based study. J Affect Disord 2004; 83: 169-175
• 6 Wijlaars L, Nazareth I, Petersen I. Trends in depression and antidepressant prescribing in children and adolescents: a cohort study in The Health Improvement Network (THIN). PLoS One 2012; 7: e33181
• 7 Skaer T, Sclar D, Robison L. Trends in prescriptions for antidepressant pharmacotherapy among US children and adolescents diagnosed with depression, 1990 through 2001: an assessment of accordance with treatment recommendations from the American Academy of Child and Adolescent Psychiatry. Clin Ther 2009; 31 (Pt 1) 1478-1487
• 8 Buckley N, McManus P. Fatal toxicity of serotonergic and other antidepressant drugs: analysis of United Kingdom mortality data. BMJ 2002; 325: 1332-1333
• 9 MacGillivray S, Arroll B, Hatcher S et al. Efficacy and tolerability of selective serotonin reuptake inhibitors compared with tricyclic antidepressants in depression treated in primary care: systematic review and meta-analysis. BMJ 2003; 326: 1014
• 10 Goldstein B, Goodnick P. Selective serotonin reuptake inhibitors in the treatment of affective disorders – II. Tolerability, safety and pharmacoeconomics. J Psychopharmacol 1998; 12: S55-S87
• 11 Vaswani M, Linda F, Ramesh S. Role of selective serotonin reuptake inhibitors in psychiatric disorders. Prog Neuropsychopharmacol Biol Psychiatry 2003; 27: 85-102
• 12 Calhoun J, Calhoun D. Prolonged bleeding time in a patient treated with sertraline. Am J Psychiatry 1996; 153: 443
• 13 Lake M, Birmaher B, Wassick S et al. Bleeding and selective serotonin reuptake inhibitors in childhood and adolescence. J Child Adolesc Psychopharmacol 2000; 10: 35-38
• 14 Pai V, Kelly M. Bruising associated with the use of fluoxetine. Ann Pharmacother 1996; 30: 786-788
• 15 Aranth J, Lindberg C. Bleeding, a side effect of fluoxetine. Am J Psychiatry 1992; 149: 412
• 16 Ottervanger J, Stricker B, Huls J et al. Bleeding attributed to the intake of paroxetine. Am J Psychiatry 1994; 151: 781-782
• 17 Andersohn F, Konzen C, Bronder E et al. Citalopram-induced bleeding due to severe thrombocytopenia. Psychosomatics 2009; 50: 297-298
• 18 Holzer L, Halfon O. Setraline and gastrointestinal bleeding in an adolescent girl. J Child Adolesc Psychopharmacol 2006; 16: 1-2
• 19 Andrade C, Sandarsh S, Chethan K et al. Serotonin reuptake inhibitors antidepressants and abnormal bleeding: a review for clinicians and a reconsideration of mechanisms. J Clin Psychiatry 2010; 71: 1565-1575
• 20 Labos C, Dasgupta K, Nedjar H et al. Risk of bleeding associated with combined use of selective serotonin reuptake inhibitors and antiplatelet therapy following acute myocardial infarction. CMAJ 2011; 183: 1835-1843
• 21 Cochran K, Cavallari L, Shapiro N et al. Bleeding incidence with concomitant use of antidepressants and warfarin. Ther Drug Monit 2011; 33: 433-438
• 22 Schalekamp T, Klungel O, Souverein P et al. Increased bleeding risk with concurrent use of selective serotonin reuptake inhibitors and coumarins. Arch Intern Med 2008; 168: 180-185
• 23 de Abajo F, Garcia-Rodriguez L. Risk of upper gastrointestinal tract bleeding associated with selective serotonin reuptake inhibitors and venlafaxine therapy: interactions with nonsteroidal anti-inflammatory drugs and effect of acid-suppressing agents. Arch Gen Psychiatry 2008; 65: 795-803
• 24 de Abajo F, Rodriguez L, Montero D. Association between selective serotonin reuptake inhibitors and upper gastrointestinal bleeding: population based case-control study. BMJ 1999; 319: 1106-1109
• 25 Dalton S, Johansen C, Mellemkjaer L et al. Use of selective serotonin reuptake inhibitors and risk of upper gastrointestinal bleeding: a population-based cohort study. Arch Intern Med 2003; 163: 59-64
• 26 Targownik L, Bolton J, Metge C et al. Selective serotonin reuptake inhibitors are associated with a modest increase in the risk of upper gastrointestinal bleeding. Am J Gastroenterol 2009; 104: 1475-1482
• 27 Wang Y, Chen Y, Tsai C et al. Short-term use of serotonin reuptake inhibitors and risk of upper gastrointenstinal bleeding. Am J Psychiatry 2014; 171: 54-61
• 28 Mortensen J, Larsson H, Johnsen S et al. Post stroke use of selective serotonin reuptake inhibitors and clinical outcome among patients with ischemic stroke: a nationwide propensity score-matched follow-up study. Stroke 2013; 44: 420-426
• 29 Auerbach A, Vittinghoff E, Maselli J et al. Perioperative use of selective serotonin reuptake inhibitors and risks for adverse outcomes in surgery. JAMA Intern Med 2013; 173: 1075-1081
• 30 Shin D, Oh Y, Eom C et al. Use of selective serotonin reuptake inhibitors as risk of stroke: a systematic review and meta-analysis. J Neurol 2014; 261: 686-695
• 31 Hackam D, Mrkobrada M. Selective serotonin reuptake inhibitors and brain hemorrhage: a meta-analysis. Neurology 2012; 79: 1862-1865
• 32 Serebruany V. Selective serotonin reuptake inhibitors and increased bleeding risk: are we missing something?. Am J Med 2006; 119: 113-116
• 33 Halperin D, Reber G. Influence of antidepressants on hemostasis. Dialogues Clin Neurosci 2007; 9: 47-59
• 34 Abdel Salam O. Fluoxetine and sertraline stimulate gastric acid secretion via a vagal pathway in anaesthetised rats. Pharmacol Res 2004; 50: 309-316
• 35 Yamaguchi T, Hidaka N, Suemaru K et al. The coadministration of paroxetine and low-dose aspirin synergistically enhances gastric ulcerogenic risk in rats. Biol Pharm Bull 2008; 31: 1371-1375
• 36 de Jong J, van den Berg P, Tobi H et al. Combined use of SSRIs and NSAIDs increases the risk of gastrointestinal adverse effects. Br J Clin Pharmacol 2003; 55: 591-595
• 37 Zullino D, Khazaal Y. Increased risk of gastrointestinal adverse effects under SSRI/NSAID combination may be due to pharmacokinetic interactions. Br J Clin Pharmacol 2005; 59: 118-119
• 38 Pedrazza E, Senger M, Rico E et al. Fluoxetine and nortriptyline affect NTPDase and 5′-nucleotidase activities in rat blood serum. Life Sci 2007; 81: 1205-1210
• 39 Schelleman H, Brensinger C, Bilker W et al. Antidepressant-warfarin interaction and associated gastrointestinal bleeding risk in a case-control study. PLoS One 2011; 6: e21447
• 40 Hampel H, Berger C, Kuss H et al. Unstable anticoagulation in the course of amitriptyline treatment. Pharmacopsychiatry 1996; 29: 33-37
• 41 Perahia D, Bangs M, Zhang Q et al. The risk of bleeding with duloxetine treatment in patients who use nonsteroidal anti-inflammatory drugs (NSAIDs): analysis of placebo-controlled trials and post-marketing adverse event reports. Drug Healthc Patient Saf 2013; 5: 211-219
• 42 Balhara Y, Sagar R, Varghese S. Bleeding gums: duloxetine may be the cause. J Postgrad Med 2007; 53: 44-45
• 43 Gross C, Klocker M, Jakob T et al. Dermatological side effects during therapy with serotonin noradrenaline reuptake inhibitors. Nervenarzt 2008; 79 (1304) 1307-1309
• 44 Chappell J, He J, Knadler M et al. Effects of duloxetine on the pharmacodynamics and pharmacokinetics of warfarin at steady state in healthy subjects. J Clin Pharmacol 2009; 49: 1456-1466
• 45 Rubell E. Does imipramine (Tofranil) cause oral bleeding?. Pediatrics 1969; 43: 144-145
• 46 König F, Stumpp W, Wolfersdorf M et al. Follow-up of Werlhof disease after onset of treatment with maprotiline. Nervenarzt 1995; 66: 60-65
• 47 Crampsey D, Douglas C, Cooke L. Nasal insertion of St John’s wort: an unusual cause of epistaxis. J Laryngol Otol 2007; 121: 279-280
• 48 Yavasoglu I, Kadikoylu G, Bolaman Z. Gingival bleeding due to venlafaxine. Ann Pharmacother 2008; 42: 144-145
• 49 Ghio L, Puppo S, Presta A. Venlafaxine and risk of upper gastrointestinal bleeding in elderly depression. Curr Drug Saf 2012; 7: 389-390
• 50 Linnebur S, Saseen J, Pace W. Venlafaxine-associated vaginal bleeding. Pharmacotherapy 2002; 22: 652-655
• 51 Benazzi F. Hemorrhages during escitalopram-venlafaxine-mirtazapine combination treatment of depression. Can J Psychiatry 2005; 50: 184
• 52 de Abajo F, Garcia-Rodriguez L. Risk of upper gastrointestinal tract bleeding associated with selective serotonin reuptake inhibitors and venlafaxine therapy: interaction with nonsteroidal anti-inflammatory drugs and effect of acid-suppressing agents. Arch Gen Psychiatry 2008; 65: 795-803
• 53 Opatrny L, Delaney J, Suissa S. Gastro-intestinal haemorrhage risks of selective serotonin receptor antagonist therapy: a new look. Br J Clin Pharmacol 2008; 66: 76-81
• 54 van Manen R, Fram D, DuMouchel W. Signal detection methodologies to support effective safety management. Expert Opin Drug Saf 2007; 6: 451-464
• 55 Gould A. Practical pharmacovigilance analysis strategies. Pharmacoepidemiol Drug Saf 2003; 12: 559-574
• 56 Ooba N, Kubota K. Selected control events and reporting odds ratio in signal detection methodology. Pharmacoepidemiol Drug Saf 2010; 19: 1159-1165
• 57 Bate A, Evans S. Quantitative signal detection using spontaneous ADR reporting. Pharmacoepidemiol Drug Saf 2009; 18: 427-436
• 58 Finney D. Statistical logic in the monitoring of reactions to therapeutic drugs. Methods Inf Med 1971; 10: 237-245
• 59 van Puijenbroek E, Bate A, Leufkens H et al. A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions. Pharmacoepidemiol Drug Saf 2002; 11: 3-10
• 60 Rothman K, Lanes S, Sacks S. The reporting odds ratio and its advantages over the proportional reporting odds ratio. Drug Saf 2004; 13: 519-523
• 61 Evans S. Pharmacovigilance: a science or fielding emergencies?. Stat Med 2000; 19: 3199-3209
• 62 Williams D, Feely J. Underreporting of adverse drug reactions: attitudes of Irish doctors. Ir J Med Sci 1999; 168: 257-261
• 63 Begaud B, Martin K, Haramburu F et al. Rates of spontaneous reporting of adverse drug reactions in France. JAMA 2002; 288: 1588
• 64 Berthold H, Schott G, Muller-Oerlinghausen B. Pharmakovigilanz: Empfehlungen zur Meldung unerwünschter Arzneimittelwirkungen durch die Ärzteschaft. Arzneiverordnung in der Praxis 2005; 32: 1-31
• 65 Martin R, Kapoor K, Wilton L et al. Underreporting of suspected adverse drug reactions to newly marketed (“black triangle”) drugs in general practice: observational study. BMJ 1998; 317: 119-120
• 66 Anglin R, Yuan Y, Moayyedi P et al. Risk of upper gastrointestinal bleeding with selective serotononin reuptake inhibitors with or without concurrent nonsteroidal anti-inflammatory use: a systematic review a metaanalysis. Am J Gastroenterol 2014; 109: 811-819
• 67 Wahab AI, Pratt N, Kalisch E et al. Comparing time to adverse drug reaction signals in a spontaneus reporting database and a claims database a case study of rofecoxib-indiced myocardial infarction and rosiglitazone-induced heart failure signals in Australia. Drug Saf 2014; 37: 53-64
• 68 Rahimi R, Abdollahi M. An update on the ability of St. John’s wort to affect the metabolism of other drugs. Expert Opin Drug Metabol Toxicol 2012; 8: 691-708
• 69 Caraci F, Crupi R, Drago F et al. Metabolic drug interactions between antidepressants and anticancer drugs: focus on selective serotonin reuptake inhibitors and hypericum extract. Curr Drug Metab 2011; 12: 570-577
• 70 Izzo A, Ernst E. Interactions between herbal medicines and prescribed drugs: an updated systematic review. Drugs 2009; 69: 1777-1798
• 71 Di Y, Li C, Xue C et al. Clinical drugs that interact with St. John’s wort and implication in drug development. Curr Pharm Des 2008; 14: 1723-1742
• 72 de Abajo F. Effects of selective serotonin reuptake inhibitors on platelet function: mechanisms, clinical outcomes and implications for use in elderly patients. Drugs Aging 2011; 28: 345-367